Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Sep;92(9):1475-1483.
doi: 10.1002/jmv.25961. Epub 2020 May 12.

Convalescent plasma transfusion for the treatment of COVID-19: Systematic review

Karthick Rajendran  1 , Narayanasamy Krishnasamy  2 , Jayanthi Rangarajan  3 , Jeyalalitha Rathinam  3 , Murugan Natarajan  3 , Arunkumar Ramachandran  1
Affiliations

Convalescent plasma transfusion for the treatment of COVID-19: Systematic review

Karthick Rajendran et al. J Med Virol. 2020 Sep.

Abstract

The recent emergence of coronavirus disease 2019 (COVID-19) pandemic has reassessed the usefulness of historic convalescent plasma transfusion (CPT). This review was conducted to evaluate the effectiveness of CPT therapy in COVID-19 patients based on the publications reported till date. To our knowledge, this is the first systematic review on convalescent plasma on clinically relevant outcomes in individuals with COVID-19. PubMed, EMBASE, and Medline databases were searched upto 19 April 2020. All records were screened as per the protocol eligibility criteria. We included five studies reporting CPT to COVID-19 patients. The main findings from available data are as follows: (a) Convalescent plasma may reduce mortality in critically ill patients, (b) Increase in neutralizing antibody titers and disappearance of SARS-CoV-2 RNA was observed in almost all the patients after CPT therapy, and (c) Beneficial effect on clinical symptoms after administration of convalescent plasma. Based on the limited scientific data, CPT therapy in COVID-19 patients appears safe, clinically effective, and reduces mortality. Well-designed large multicenter clinical trial studies should be conducted urgently to establish the efficacy of CPT to COVID-19 patients.

Keywords: COVID-19; SARS-CoV-2; convalescent plasma transfusion (CPT); neutralizing antibody.

PubMed Disclaimer

Conflict of interest statement

The authors declare that there are no conflict of interests.

Figures

Figure 1
Figure 1
PRISMA Flow chart of study selection. CPT, convalescent plasma transfusion
See this image and copyright information in PMC

References

    1. World Health Organization . Coronavirus disease 2019 (COVID‐19) ‐ Situation Repor ‐ 90 (April 19, 2020). https://www.who.int/emergencies/diseases/novel‐coronavirus‐2019/situatio.... Accessed April 19, 2020.
    1. World Health Organization . Clinical management of severe acute respiratory infection (SARI) when COVID‐19 disease is suspected. Interim guidance 13 March 2020. https://www.who.int/publications‐detail/clinical‐management‐of‐severe‐ac.... Accessed April 18, 2020.
    1. Casadevall Arturo, Pirofski Liise‐anne. The convalescent sera option for containing COVID‐19. J Clin Invest. 2020;130(4):1545‐1548. - PMC - PubMed
    1. Food and Drug Administration . Recommendations for Investigational COVID‐19 Convalescent Plasma, Content current as of: 04/13/2020. https://www.fda.gov/vaccines‐blood‐biologics/investigational‐new‐drug‐in.... Accessed April 18, 2020.
    1. Moher David, Shamseer Larissa, Clarke Mike, et al. Preferred reporting items for systematic review and meta‐analysis protocols (PRISMA‐P) 2015 statement. Syst Rev. 2015;4:1. - PMC - PubMed

Publication types